### CONTENTS

Dedication ...................................................................................................................... v
Preface ......................................................................................................................... vii
Contributors ................................................................................................................... xi

#### Part I. Introduction

- **Chapter 1. Cardiac Safety of Noncardiac Drugs: Historical Recollections**
  - Raymond John Lipicky
  - p. 3

#### Part II. Preclinical and Pharmacogenomic Cardiac Safety Evaluations

- **Chapter 2. Molecular Physiology of Ion Channels That Control Cardiac Repolarization**
  - Jeanne M. Nerbonne and Robert S. Kass
  - p. 13
- **Chapter 3. Cellular, Molecular, and Pharmacologic Mechanisms Underlying Drug-Induced Cardiac Arrhythmogenesis**
  - Charles Antzelevitch
  - p. 37
- **Chapter 4. hERG Assay, QT Liability, and Sudden Cardiac Death**
  - Arthur M. Brown
  - p. 67
- **Chapter 5. Pharmacogenomics in Drug Development: When and How to Apply**
  - Richard Judson and Arthur J. Moss
  - p. 83

#### Part III. Clinical Methodologies and Technical Aspects of Assessing Cardiac Safety of Investigational Drugs: Focus on Cardiac Repolarization

- **Chapter 6. Assessment of Ventricular Repolarization From Body-Surface ECGs in Humans**
  - Jean-Philippe Couderc and Wojciech Zareba
  - p. 107
- **Chapter 7. ECG Acquisition and Signal Processing: 12-Lead ECG Acquisition**
  - Justin L. Mortara
  - p. 131
- **Chapter 8. Digital 12-Lead Holter vs Standard Resting Supine Electrocardiogram for the Assessment of Drug-Induced QTc Prolongation: Assessment by Different Recording and Measurement Methods**
  - Nenad Sarapa
  - p. 147
- **Chapter 9. Holter Monitoring for QT: The RR Bin Method in Depth**
  - Fabio Badilini and Pierre Maison-Blanche
  - p. 167
Part IV. Application of Electrocardiology in Clinical Research

Chapter 10. Fundamentals of ECG Interpretation in Clinical Research and Cardiac Safety Assessment ......................................................... 189
   Ihor Gussak, Robert Kleiman, and Jeffrey S. Litwin

Chapter 11. Design and Conduct of the Thorough Phase I ECG Trial for New Bioactive Drugs .......................................................... 205
   Joel Morganroth

Chapter 12. Use of ECGs in Support of Cardiac Safety in Phase II and III Clinical Trials ................................................................. 223
   Martin P. Bedigian

Chapter 13. Cardiac Arrhythmia Assessment in Phase IV Clinical Studies ........................................................... 229
   Gerald A. Faich and Annette Stemhagen

Chapter 14. Statistical Analysis Plans for ECG Data: Controlling the Intrinsic and Extrinsic Variability in QT Data .......................... 239
   Alan S. Hollister and Timothy H Montague

Chapter 15. Interpretation of Clinical ECG Data: Understanding the Risk From Non-Antiarrhythmic Drugs ............................................. 259
   Rashmi R. Shah

Part V. Regulatory Considerations

Chapter 16. The FDA’s Digital ECG Initiative and Its Impact on Clinical Trials ................................................................. 301
   Barry D. Brown

Chapter 17. Quality Control and Quality Assurance for Core ECG Laboratories ................................................................. 329
   Amy M. Annand-Furlong

   Scott Grisanti and Robert Brown

Index ........................................................................................................................... 355
Cardiac Safety of Noncardiac Drugs
Practical Guidelines for Clinical Research and Drug Development
Morganroth, J.; Gussak, I. (Eds.)
2005, XII, 362 p., Hardcover
ISBN: 978-1-58829-515-6
A product of Humana Press